Cover Image
市場調查報告書

嗜中性白血球低下症:開發中產品分析

Neutropenia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192734
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
嗜中性白血球低下症:開發中產品分析 Neutropenia - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 92 Pages
簡介

嗜中性白血球低下症,是負責擊退感染疾病的嗜中性白血球的數量異常少的狀態。徵兆與症狀有發熱、頻繁感染、口腔炎、齒齦感染疾病、排尿障礙等。

本報告提供嗜中性白血球低下症的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

嗜中性白血球低下症概要

治療藥的開發

  • 開發中產品的概要

嗜中性白血球低下症:企業開發中的治療藥

嗜中性白血球低下症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

嗜中性白血球低下症:企業開發中的產品

嗜中性白血球低下症的治療藥的開發企業

  • Apotex Inc.
  • Biogenomics Limited
  • Cellerant Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Limited
  • Ligand Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Prolong Pharmaceuticals, LLC
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Therapeutic Proteins International, LLC
  • 東光藥品工業
  • USV Limited

嗜中性白血球低下症:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

嗜中性白血球低下症:最近的開發平台趨勢

嗜中性白血球低下症:暫停中的計劃

嗜中性白血球低下症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9728IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H2 2017, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 2, 4, 6, 9 and 3 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neutropenia - Overview
    • Neutropenia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Neutropenia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neutropenia - Companies Involved in Therapeutics Development
    • Adello Biologics LLC
    • Arven Ilac
    • BeyondSpring Pharmaceuticals Inc
    • Biocon Ltd
    • Cantex Pharmaceuticals Inc
    • Cellerant Therapeutics Inc
    • Cleveland BioLabs Inc
    • Coherus BioSciences Inc
    • Dr. Reddy's Laboratories Ltd
    • Eurofarma Laboratorios SA
    • Ligand Pharmaceuticals Inc
    • Lupin Ltd
    • Merck & Co Inc
    • Mycenax Biotech Inc
    • Prolong Pharmaceuticals LLC
    • Richter Gedeon Nyrt
    • Sandoz International GmbH
    • USV Pvt Ltd
  • Neutropenia - Drug Profiles
    • ACN-8337 - Drug Profile
    • ARVMIC-02 - Drug Profile
    • CBLB-612 - Drug Profile
    • dociparstat sodium - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • filgrastim - Drug Profile
    • LG-7455 - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim - Drug Profile
    • pegfilgrastim (recombinant) - Drug Profile
    • plinabulin - Drug Profile
    • posaconazole - Drug Profile
    • romyelocel-L - Drug Profile
    • ST-7 - Drug Profile
    • tamibarotene - Drug Profile
  • Neutropenia - Dormant Projects
  • Neutropenia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Neutropenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Neutropenia - Pipeline by Adello Biologics LLC, H2 2017
  • Neutropenia - Pipeline by Arven Ilac, H2 2017
  • Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
  • Neutropenia - Pipeline by Biocon Ltd, H2 2017
  • Neutropenia - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
  • Neutropenia - Pipeline by Cellerant Therapeutics Inc, H2 2017
  • Neutropenia - Pipeline by Cleveland BioLabs Inc, H2 2017
  • Neutropenia - Pipeline by Coherus BioSciences Inc, H2 2017
  • Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
  • Neutropenia - Pipeline by Eurofarma Laboratorios SA, H2 2017
  • Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H2 2017
  • Neutropenia - Pipeline by Lupin Ltd, H2 2017
  • Neutropenia - Pipeline by Merck & Co Inc, H2 2017
  • Neutropenia - Pipeline by Mycenax Biotech Inc, H2 2017
  • Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
  • Neutropenia - Pipeline by Richter Gedeon Nyrt, H2 2017
  • Neutropenia - Pipeline by Sandoz International GmbH, H2 2017
  • Neutropenia - Pipeline by USV Pvt Ltd, H2 2017
  • Neutropenia - Dormant Projects, H2 2017
  • Neutropenia - Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Neutropenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top